COGNICURRENT

New studies suggest that certain diabetes and obesity drugs may lower the risk of addiction to alcohol and other drugs.

A recent study indicates that the effects of Ozempic, an anti-obesity drug, can continue for a year after treatment cessation, highlighting ongoing challenges in long-term weight management.

Research indicates that stopping weight loss injections can lead to significant weight regain, raising concerns about their long-term effectiveness.

In Slovakia, the anti-obesity drug Ozempic and similar medications are increasingly prescribed by doctors across various specialties, not limited to endocrinology.

A police operation in Salgueiro, Brazil, led to the seizure of counterfeit obesity medications and unregistered electronics.

The article discusses the increasing trend of purchasing weight loss medications online, particularly GLP-1 drugs, and the associated risks with unregulated sources.

A new obesity drug trial reveals significant weight loss but raises concerns as patients abandon the study due to fears of losing too much weight.

Recent trials involving the weight loss drug retatrutide have raised concerns after participants reported significant weight loss, but also higher than normal dropout rates due to side effects.

An Indian pharmaceutical company is set to launch generic versions of obesity drugs Ozempic and Wegony at significantly reduced prices in India.

New reviews of popular weight loss drugs like Ozempic and Mounjaro conclude that they are effective in reducing weight but raise concerns about the significant involvement of the manufacturers in the studies.

The article discusses the recent advancements in obesity medications and the challenges of making them accessible to the broader population.

There has been a surge in illegal sales of unauthorized diet drugs impersonating Korean Lilly, particularly through social media, amidst growing interest in obesity treatments.

Semaglutide by Novo Nordisk is the first drug approved for obesity treatment that achieves weight loss comparable to bariatric surgery, while Eli Lilly's tirzepatide is expected to gain approval soon after showing efficacy and safety in clinical trials.

Novo Nordisk's new oral obesity drug Wegovy offers only a minor advantage over Eli Lilly in the ongoing pharmaceutical battle for obesity treatments.

The article discusses GLP-3s, a new generation of weight-loss drugs that target multiple hormones to enhance obesity treatment.

A study suggests implementing strategic programs for GLP-1 medications to address the global obesity crisis, while also warning about the rebound effect of drugs like Ozempic.

Jordan is experiencing a significant increase in the use of weight loss injections due to rising obesity rates, with medical warnings regarding the risks of using such drugs without professional supervision.

The expiration of patents for weight loss drugs is paving the way for the introduction of generic alternatives in the global obesity medication market.

In China, the increasing obesity of pets is driving pharmaceutical companies to develop weight-loss drugs for animals, as pet owners grapple with health risks versus their pets' cute appearances.

The article discusses the anticipated developments of leading drugs in 2026, focusing on GLP-1 agonists, new multi-target compounds, and advancements in treatments for obesity and diabetes, along with their expanding applications in other health conditions.

New obesity drugs, GLP-1 analogs, show potential in slowing the aging of organs in both mice and HIV patients, with possible applications beyond diabetes and obesity.